

Intravenous Alteplase compared to Tenecteplase in Acute Ischemic Stroke



Research Question

In patients with acute ischemic stroke eligible for intravenous thrombolysis, is tenecteplase non-inferior to alteplase for 90-day excellent outcome (mRS 0-1) assessed using the modified Rankin Scale?*



LARGE SIMPLE TRIAL (N=1600)

PRAGMATIC ELIGIBILITY CRITERIA

DEFERRED CONSENT AND E-CONSENTS

RAPID RANDOMIZATION AND TECH ENABLED DATA MONITORING

PRIMARY TRIAL DATA COMPLEMENTED BY REGISTRIES

BLINDED PRIMARY OUTCOME ASCERTAINED CENTRALLY



*Non-inferiority met if the lower 95% confidence interval of difference in primary outcome rates between tenecteplase vs. alteplase in intention-to-treat (ITT) analysis > -5%